167 related articles for article (PubMed ID: 31872559)
1. Chymase inhibition retards albuminuria in type 2 diabetes.
Bivona BJ; Takai S; Seth DM; Satou R; Harrison-Bernard LM
Physiol Rep; 2019 Dec; 7(24):e14302. PubMed ID: 31872559
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice.
Terai K; Jin D; Watase K; Imagawa A; Takai S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050674
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.
Park S; Bivona BJ; Ford SM; Xu S; Kobori H; de Garavilla L; Harrison-Bernard LM
Hypertension; 2013 Feb; 61(2):465-71. PubMed ID: 23213190
[TBL] [Abstract][Full Text] [Related]
4. Chymase inhibition protects diabetic rats from renal lesions.
Zhang M; Huang W; Bai J; Nie X; Wang W
Mol Med Rep; 2016 Jul; 14(1):121-8. PubMed ID: 27176496
[TBL] [Abstract][Full Text] [Related]
5. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.
Ye M; Wysocki J; William J; Soler MJ; Cokic I; Batlle D
J Am Soc Nephrol; 2006 Nov; 17(11):3067-75. PubMed ID: 17021266
[TBL] [Abstract][Full Text] [Related]
6. Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.
Rossing P; Strand J; Avogaro A; Becka M; Kanefendt F; Otto C
Nephrol Dial Transplant; 2021 Dec; 36(12):2263-2273. PubMed ID: 33367744
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes.
Lin Y; Sun Z
J Endocrinol; 2011 May; 209(2):185-91. PubMed ID: 21307121
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
[TBL] [Abstract][Full Text] [Related]
9. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
11. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
12. Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Wong MY; Saad S; Wong MG; Stangenberg S; Jarolimek W; Schilter H; Zaky A; Gill A; Pollock C
PLoS One; 2020; 15(6):e0234617. PubMed ID: 32555665
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.
Maeda Y; Inoguchi T; Takei R; Sawada F; Sasaki S; Fujii M; Kobayashi K; Urata H; Nishiyama A; Takayanagi R
Am J Physiol Renal Physiol; 2010 Dec; 299(6):F1328-38. PubMed ID: 20881036
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.
El Boustany R; Taveau C; Chollet C; Velho G; Bankir L; Alhenc-Gelas F; Roussel R; Bouby N
J Diabetes Complications; 2017 Jun; 31(6):929-932. PubMed ID: 28412033
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of hyperfiltration and renin angiotensin system activation on development of chronic kidney disease in diabetic db/db mice.
Hartono SP; Knudsen BE; Lerman LO; Textor SC; Grande JP
BMC Nephrol; 2014 Apr; 15():58. PubMed ID: 24708836
[TBL] [Abstract][Full Text] [Related]
17. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats.
Thöne-Reinke C; Simon K; Richter CM; Godes M; Neumayer HH; Thormählen D; Hocher B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S76-9. PubMed ID: 15838365
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
Sedeek M; Gutsol A; Montezano AC; Burger D; Nguyen Dinh Cat A; Kennedy CR; Burns KD; Cooper ME; Jandeleit-Dahm K; Page P; Szyndralewiez C; Heitz F; Hebert RL; Touyz RM
Clin Sci (Lond); 2013 Feb; 124(3):191-202. PubMed ID: 22920224
[TBL] [Abstract][Full Text] [Related]
20. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Yoshida S; Hashimoto T; Kihara M; Imai N; Yasuzaki H; Nomura K; Kiuchi Y; Tamura K; Ishigami T; Hirawa N; Toya Y; Kitamura H; Umemura S
Nephron Exp Nephrol; 2009; 111(1):e20-30. PubMed ID: 19052474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
